Moderna, Inc.

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna’s COVID-19 Booster Vaccine

Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna’s COVID-19 Booster Vaccine

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union

Moderna, Inc.: Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)

Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)

Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries